Dr. Chad Mirkin
Co-founder
Flashpoint Therapeutics
Flashpoint Therapeutics is a clinical‑stage biotech that uses a proprietary nanotechnology platform to create structural nanomedicines capable of co‑delivering precisely engineered combinations of nucleic acids, peptides, and small molecules to specific cell types. By controlling payload ratios, nanoscale architecture, and activation kinetics, the platform boosts potency, stability and safety across more than 60 cell types and supports modalities such as mRNA, DNA, proteins and CRISPR for applications like cancer immunotherapy.
- Biotechnology
Updated 5 months ago
Funding
Raised to date
$10MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Current therapeutic modalities often deliver single agents with limited control over payload ratios, cellular targeting, and activation timing, resulting in suboptimal potency, stability, and safety. This lack of precise co‑delivery hampers the effectiveness of treatments such as mRNA vaccines, peptide drugs, and gene‑editing tools, especially in complex diseases like cancer.
Solution
Flashpoint Therapeutics leverages a proprietary nanotechnology platform to create structural nanomedicines that co‑deliver precisely engineered combinations of nucleic acids, peptides, and small molecules to specific cell types. By tuning nanoscale architecture, the platform ensures defined stoichiometry, optimized structure‑function relationships, and synchronized activation kinetics, enhancing potency, stability, and safety across >60 cell types. The modular system supports a wide range of modalities—including mRNA, DNA, proteins, and CRISPR components—allowing rapid development of first‑in‑class candidates such as cancer immunotherapies that orchestrate coordinated anti‑tumor immune responses. Clinical‑stage candidates have demonstrated superior product profiles, including markedly increased potency and improved delivery to immune cells and across the blood‑brain barrier.
Target Audience
Primary customers are pharmaceutical and biotech companies developing oncology, immunotherapy, and gene‑editing therapeutics that require precise multi‑component delivery, as well as research institutions seeking advanced nanomedicine platforms for preclinical studies.
Features
- All‑in‑one nanostructures that co‑deliver diverse payloads with precise ratio control
- Chemically tunable kinetics for synchronized multi‑pathway activation
- Demonstrated 500%+ potency increase over lipid nanoparticle mRNA formulations
- 35× enhanced delivery to immune cells and 80× stronger innate immune activation
- 50× improved circulation stability and 30× better intracellular peptide delivery
- Capability to target >60 distinct cell types, including crossing the blood‑brain barrier
- Platform validated in IND‑cleared candidates manufactured at GMP scale
- Supports delivery of mRNA, DNA, proteins, CRISPR components, and small molecules